F. Markus Leweke, MD

Trials

Studies that name F. Markus Leweke, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:51 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT02926859 · Enhancing Recovery in Early Schizophrenia

  Central Institute of Mental Health, Mannheim · active not recruiting · Schizophrenia · principal investigator
• Ph1
  NCT02492074 · Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study

  Central Institute of Mental Health, Mannheim · withdrawn · Healthy Volunteers, Modeling Psychosis · principal investigator
• Ph2
  NCT02088060 · A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients

  Central Institute of Mental Health, Mannheim · terminated · Schizophrenia · principal investigator
• Ph1
  NCT00916201 · Evaluation Study of New Compounds With Potential Use in Schizophrenia

  Central Institute of Mental Health, Mannheim · withdrawn · Schizophrenia · principal investigator
• Ph2/Ph3
  NCT00637234 · Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia

  University of Cologne · completed · Schizophrenia · study director
• Ph2
  NCT00309413 · A Clinical Trial on the Antipsychotic Properties of Cannabidiol

  University of Cologne · completed · Schizophrenia, Psychotic Disorders · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 05:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 6 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.